DE EN
  • Array

    Our Innovation

A new class of effective and affordable medicine for pets

HypoPet has developed a novel and innovative vaccine platform that is based on non-infectious virus-like particles in order to treat chronic inflammatory diseases, cancer and allergy in pets. The VLPs represent a highly ordered molecular assembly system eliciting strong antibody responses. HypoPet can easily adapt the innovative VLP vaccine platform to target any disease-associated molecule taking advantage of the latest and most effective innovations in human medicines, specifically monoclonal antibody therapy, and turn them into a new, efficacious and affordable class of veterinary vaccine-based medicine. Our vaccines instruct the pet’s immune system to make target-specific antibodies, which can inhibit any disease-promoting or disease-associated molecules. HypoPet's platform technology can also be accommodated to produce conventional vaccines suitable for preventing infectious diseases in companion animals and livestock.

Related Literature

Zeltins A, Bachmann MF. (2017) Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. NPJ Vaccines. 23;2:30